Supply Chain Resource Council Reports
About the Supply Chain Resource Council (SCRC)
The SCRC is comprised of over 130 supply chain and health care leaders from across the field with the goal of understanding the extent to which supply shortages, disruptions, and policy are impacting hospital and patient care settings, as well as capturing and documenting solutions.
This report includes information, strategies and solutions from the SCRC members, but does not necessarily reflect the policy positions of the AHA.
2025 SCRC Reports
August/September 2025 Report
This month's SCRC meeting focused on on tariff strategies and their evolving impact on health care supply chains. Members shared updates on supplier engagement, country of origin and data modeling dashboards, and the development of internal tools to manage tariff-related risks. Pharmaceutical supply chain resilience, cybersecurity risks, and product shortages were also discussed.
July 2025 Report
This month's SCRC meeting focused on the extension of the reciprocal tariffs modification to August 1, 2025, ongoing impacts of tariff-related fees and surcharges and proactive strategies for mitigating supply chain risks. Council members discussed vendor negotiations, sourcing alternatives and the import
June 2025 Presentations
The June 2025 SCRC meeting featured presentations from four supply chain risk management firms. The presentations showcased the capabilities of their analytics and intelligence platforms, such as global monitoring, real-time alerts, logistics impact assessment, and visibility into upstream supply chain tiers.
May 2025 Report
The May SCRC meeting focused on tariffs, executive orders affecting pharmaceutical manufacturing and life sciences research, and the Massimo cybersecurity incident. Council members shared strategies for mitigating tariff-related cost increases, discussed sourcing alternatives, and expressed interested in third-party risk management tools.
April 2025 Report
This month’s Supply Chain Resource Council report highlights the ongoing advocacy by the AHA for tariff exemptions on health care products. Additionally, the report addresses bill-only fees charged by implant vendors and legislative efforts in multiple states to remove DEHP and PVC from IV bags and tubing.
March 2025 Report
BD BACTEC media and Baxter IV manufacturing lines have returned to normal operations, while health care organizations continue to assess tariffs. California legislation regarding IV products was discussed, as was the Class I recall of Baxter’s Sigma and Spectrum IQ infusion systems.
February 2025 Report
The focus of this month’s meeting was the tariff strategies hospitals and health care organizations were considering or adopting to better understand potential changes to product pricing for their organizations.